Among the growing names in the international forex market, CWG Markets is gradually attracting attention as a multi-asset broker offering forex and CFD trading services for global retail traders.

This article provides an overview of information about CWG Markets, including its regulations, trading products, account types, copy trading services, platforms, deposits and withdrawals, and trading conditions.

What is CWG Markets?

CWG Markets is an international online forex and CFD broker that provides access to various financial markets, including forex, commodities, indices, stocks, and cryptocurrencies.

The broker focuses on providing flexible trading conditions for both beginner and experienced traders through multiple account types, competitive leverage options, and support for MetaTrader platforms.

CWG Markets has established offices in several financial regions worldwide, including:

• London
• Singapore
• Dubai
• South Africa
• Mexico
• Vietnam
• Nigeria

The broker continues expanding its services globally while focusing on retail trading accessibility and modern trading infrastructure.

Join the CWG Markets trading community here:
https://t.me/+3_in_jHpP4hlOTE1

Is CWG Markets Regulated?

Regulation is one of the most important factors traders consider when choosing a broker.

CWG Markets operates through multiple regulated entities.

FCA Regulation

CWG Markets Ltd is registered with the United Kingdom’s Financial Conduct Authority (FCA) under reference number 785129.

The FCA is recognized as one of the world’s leading financial regulatory authorities and is known for maintaining strict regulatory standards for financial service providers operating in the UK market.

This regulation helps strengthen CWG Markets’ global regulatory profile and reinforces the broker’s commitment to compliance, transparency, and international financial standards.

VFSC Regulation

CWG Markets (VU) is authorized and regulated by the Vanuatu Financial Services Commission (VFSC) under registration number 41694.

The company is registered at:

1276, Govant Building, Kumul Highway, Port Vila, Vanuatu.

The license authorizes the broker to conduct securities trading activities and provide financial services to clients.

FSCA Regulation

CWG MARKETS SA (PTY) LTD is authorized as a Financial Service Provider (FSP) by the Financial Sector Conduct Authority (FSCA) in South Africa under FSP number 54031.

These regulatory registrations help strengthen the broker’s international presence and operational credibility.

Trading Products Available at CWG Markets

CWG Markets provides traders with access to multiple financial instruments across global markets.

Forex

The broker offers trading on major, minor, and exotic currency pairs in the global forex market.

Precious Metals

Traders can access precious metal products such as gold and silver, which are commonly used as safe-haven assets during periods of market uncertainty.

Stock CFDs

CWG Markets also provides CFD trading on global stocks, allowing traders to speculate on stock price movements without directly owning the underlying shares.

Commodity Contracts

Commodity trading products are available for traders interested in diversified market exposure.

Cryptocurrencies

The broker offers cryptocurrency-related CFD products, giving traders exposure to digital asset price movements.

Indices

CWG Markets supports trading on major global indices linked to international stock markets.

Energy Products

Energy trading instruments such as crude oil products are also available through the broker’s trading platform.

The wide range of trading instruments allows traders to diversify their trading strategies across different asset classes.

Trading Platforms at CWG Markets

CWG Markets supports both MetaTrader 4 (MT4) and MetaTrader 5 (MT5), which are among the most widely used trading platforms in the forex industry.

MetaTrader 4 (MT4)

MT4 remains popular among forex traders because of its:

• User-friendly interface
• Technical analysis tools
• Expert Advisors (EA) support
• Fast order execution
• Multi-device compatibility

MetaTrader 5 (MT5)

MT5 offers additional features for traders looking for more advanced trading functionality, including:

• More technical indicators
• Additional order types
• Faster processing speeds
• Improved charting tools
• Multi-asset trading support 

Both platforms are available for desktop, mobile, and web trading.

Copy Trading at CWG Markets

Copy trading has become increasingly popular among beginner traders who want to participate in financial markets while learning from more experienced traders.

CWG Markets also offers copy trading services, allowing users to follow and copy trading strategies from other traders automatically.

Some potential advantages of copy trading include:

• Easier access for beginner traders
• Learning from experienced traders
• Automated trade execution
• Portfolio diversification opportunities
• Reduced need for manual market analysis

However, traders should remember that copy trading still involves financial risk, and past trading performance does not guarantee future results.

Account Types at CWG Markets

CWG Markets offers several account types designed for traders with different experience levels and trading preferences.

Basic Account

The Basic Account is designed for beginner traders looking for lower trading complexity and commission-free trading.

Key features include:

• Minimum deposit: $50
• Spreads from 1.5 pips
• Maximum leverage: 1:2000
• Commission: $0 per side
• Stop out level: 50%
• Islamic account available

Advanced Account

The Advanced Account is designed for traders seeking tighter spreads and more professional trading conditions.

Key features include:

• Minimum deposit: $200
• Spreads from 0.0 pips
• Maximum leverage: 1:2000
• Commission: $3 per side
• Stop out level: 50%
• Islamic account available

Cent Account

The Cent Account is suitable for beginner traders who want to trade with smaller capital exposure.

Key features include:

• Minimum deposit: $10
• Spreads from 2.2 pips
• Maximum leverage: 1:1000
• Commission-free trading
• Stop out level: 50%
• Islamic account available

The availability of different account types allows traders to choose trading conditions that match their experience and risk tolerance.

Deposits and Withdrawals at CWG Markets

CWG Markets supports multiple payment methods for global clients, including local payment solutions and cryptocurrency transfers.

Supported deposit and withdrawal methods include:

• Bank transfers
• Local payment gateways
• Help2Pay
• Cryptocurrency payments (USDT ERC20/TRC20)
• Regional payment systems for Southeast Asia and Africa

The broker supports multiple currencies including:

• USD
• EUR
• GBP
• VND
• CNY
• THB
• NGN
• ZAR
• KES
• GHS

Most payment methods are commission-free, with processing times ranging from instant processing to within 72 hours depending on the payment channel used.

CWG Markets also supports local deposit methods for Vietnamese traders, helping improve transaction convenience for users in Vietnam.

Promotions and Bonuses

CWG Markets currently offers a $50 welcome bonus promotion for traders in Vietnam.

Promotional campaigns may vary depending on region and account eligibility conditions.

Register and explore CWG Markets here:
https://secure.cwgtm.com/activity/welcome-bonus/index.html

Advantages of CWG Markets

Some advantages associated with CWG Markets include:

• Support for MT4 and MT5
• Copy trading availability
• High leverage options up to 1:2000
• Multiple account types
• Low minimum deposit requirements
• Islamic account support
• Wide range of trading instruments
• Local payment support in Vietnam
• International business presence

Disadvantages of CWG Markets

Despite its advantages, traders should also consider potential limitations.

High Leverage Risk

Although leverage up to 1:2000 may increase trading flexibility, it also significantly increases trading risk, especially for inexperienced traders.

Market Risk

Like all forex and CFD brokers, trading through CWG Markets involves substantial market risk and may not be suitable for all investors.

Final Thoughts

CWG Markets is an international forex and CFD broker offering access to multiple financial markets through MT4 and MT5 trading platforms.

With regulated entities under VFSC and FSCA, multiple account types, copy trading support, flexible deposit methods, and a wide range of trading products, the broker continues expanding its presence among global retail traders.

For traders looking for access to forex, precious metals, stock CFDs, commodities, cryptocurrencies, indices, and energy products through a broker with flexible leverage and modern trading platforms, CWG Markets may be one of the brokers worth exploring.

CTA: Telegram/Fanpage/Welcome Bonus $50

HONG KONG, May 29, 2026 (GLOBE NEWSWIRE) — AUAU Technology today announced the official global launch of its all-in-one sports and fitness business solution, auau.io. Designed specifically to empower small-to-medium-sized gyms, yoga studios, Pilates centers, dance studios and all sports centers, the platform provides a plug-and-play SaaS ecosystem that liberates business owners from tedious administrative tasks, allowing them to focus entirely on training quality and brand expansion.

Entering the global market as a highly stabilized, market-proven system, the platform is already trusted by over 500 brands across Asia particularly in Hong Kong and Malaysia. The software’s robust architecture was developed by the Onebox Creative Group, a renowned digital agency with over a decade of experience providing enterprise-grade business consulting and global IT solutions.

As a comprehensive studio and sports centers management tool, auau.io seamlessly integrates automated online booking, payment integration, and advanced customer relationship management (CRM) into a single operational hub. To accommodate the demands of a global clientele, the newly launched global version fully supports multi-language interfaces, multi-currency settlements, and cross-time zone scheduling. Built entirely on cloud-based infrastructure, studio owners can manage their operations anytime, anywhere, via mobile or web browser, without incurring high hardware costs.

“Our mission is to define a new standard of success for the next generation of sports and fitness entrepreneurs,” said Ms. Peggy Lee and Mr. Ryo Chan, co-founders of AUAU Technology. “By automating online payments, reducing manual financial reconciliation, and providing real-time data on member retention, our platform acts as a digital operational partner.”

“I’m a woman who started with zero tech background. After working in a technology company, I saw how difficult it was for a studio owner, especially women, to run their sport and wellness business. So I built AUAU. The easiest all-in-one appointment software for studios. It’s simple, no IT knowledge needed, and designed to grow with the community and the entire industry,” said Ms. Peggy Lee.

Beyond basic administration, the software actively drives revenue. The system automatically generates comprehensive financial reports and incorporates powerful promotional features, including targeted WhatsApp marketing, to enhance member retention and secure new leads.

Fitness and sports center operators looking to streamline their operations are encouraged to experience the system trusted by over 500 Asian brands. To learn more about the software or to schedule a personalized demonstration, visit the official website at www.auau.io.

About AUAU Technology

AUAU Technology is a premier SaaS provider specializing in sports and fitness studio management software. Developed by the digital experts at Onebox Creative Group, auau.io offers an all-in-one studio, club, gym and sports center management tool featuring online booking, payment integration, HR Management and CRM capabilities. Currently empowering over 500 fitness, yoga, and Pilates studios across Asia particularly in Hong Kong and Malaysia, the company provides plug-and-play, cloud-based operational solutions designed to help global sports and wellness entrepreneurs automate administration and scale their businesses.

Media Contact

Ryo Chan
Managing Director, AUAU Technology

Phone: +852 98005891, +60 12838 3162

Email: ryo.chan@auau.io
Website: www.auau.io

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b9225364-79dc-4595-95a0-10a7e3be7ab1

Tarrytown, New York, May 29, 2026 (GLOBE NEWSWIRE) — ENT & Allergy Associates, the nation’s largest ENT and Allergy practice, today announced a series of strategic expansions, relocations, and operational enhancements across its growing footprint. These initiatives reflect ENTA’s continued investment in improving patient access, modernizing clinical environments, and strengthening its presence in both established and emerging markets.

As part of this effort, ENTA recently consolidated its two Astoria, Queens offices into a newly developed 10,900 square-foot state-of-the-art clinical facility located at 28-18 31st Street, 2nd Floor, Astoria, NY. This investment reinforces ENTA’s strategy of strengthening key urban markets through thoughtful consolidation—bringing services together to improve efficiency, expand capacity, and deliver a more integrated care experience for patients.

ENTA will also relocate its Upper West Side office in June 2026 to a larger, more centrally located facility at 2431 Broadway. The new 8,900 square-foot office will support expanded services, improve patient flow, and accommodate continued growth in one of Manhattan’s busiest neighborhoods.

Both the Astoria and Upper West Side locations will serve as launch sites for ENTA’s newly developed walk-in care model, designed to further expand patient access and offer greater flexibility for patients seeking same-day, on-demand specialty care.

In Pennsylvania, ENTA continues to strengthen its suburban presence with the relocation of its Willow Grove office in the third quarter of 2026 to a newly upgraded 4,845 square-foot facility at 400 Horsham Road in Horsham, PA. The relocation will also introduce ENT services to the site, broadening the location’s clinical capabilities alongside its existing allergy and immunology offerings.

ENTA’s expansion efforts are also supported by a major technology transformation, with the organization set to implement the Epic electronic health record platform in November 2026. This transition will unify clinical and operational systems across the enterprise, enabling real-time access to patient information, improving coordination across care teams, and enhancing the overall patient and provider experience. In addition, ENTA is implementing Workday Financials and Procurement, with a targeted go-live date of July 1, 2026. This enterprise-wide initiative will modernize the organization’s financial and procurement operations, providing enhanced visibility, improved reporting capabilities, and more efficient management of purchasing and supplier relationships.

“These initiatives represent an important milestone in ENTA’s continued growth,” said Daniel Blum, Chief Executive Officer of ENTA. “As we continue to expand strategically across our markets, we remain focused on creating a more connected, accessible, and patient-centered model of specialty care. By investing in modern facilities and evolving how care is delivered, we are positioning ENTA to better serve our communities while supporting long-term growth across the organization.”

For more information about ENTA, to find a local office, or to schedule an appointment, please visit www.entandallergy.com or call 1-855-ENTA-DOC.

About the ENT & Allergy Associates Network:

ENT & Allergy Associates (ENTA) is the largest ENT, Allergy, and Audiology network in the country, with over 475 clinicians who practice in over 80 clinical locations throughout New York, New Jersey, Pennsylvania, and Texas. Each ENTA clinical office is comprised of world-class physicians who are specialists and sub-specialists in their respective fields, providing the highest level of expertise and care. With a wide range of services including Adult and Pediatric ENT & Allergy, Voice and Swallowing, Advanced Sinus and Skull Base Surgery, Facial Plastics and Reconstructive Surgery, Treatment of Disorders of the Inner Ear and Dizziness, Asthma-related services, Diagnostic Audiology, Hearing Aid Dispensing, Sleep and CT Services, ENTA is able to meet the needs of patients of all ages. ENTA is also affiliated with some of the most prestigious medical institutions in the world. Each year ENTA physicians are voted ‘Top Doctor’ by Castle Connolly, a true testament to the exceptional care and service they provide to their patients.

CONTACT: Jason Campbell ENT & Allergy Associates 914-984-2531 jcampbell@entandallergy.com 

Jakarta, Indonesia, May 28, 2026 (GLOBE NEWSWIRE) —

Held at the newly established AIMS Indonesia Office in central Jakarta

AIMS officially launched AIMS Indonesia on 25th May 2026, marking a major milestone in the company’s regional expansion and reinforcing its long-term commitment to Southeast Asia’s largest economy.

The Grand Opening celebrated a defining achievement for the company: securing the BAPPEBTI licence, the regulatory authorisation that formally permits AIMS to operate in Indonesia. With this approval, AIMS Indonesia is fully authorised to serve the Indonesian market with high standards of compliance, fund security, and institutional-grade trading infrastructure.

Held at the newly established AIMS Indonesia Office in central Jakarta, the event welcomed more than 300 guests, including industry leaders, strategic partners, clients, media representatives, and AIMS delegates from across the globe.

The evening featured a Lamborghini Huracán displayed beneath a custom-built LED tunnel, alongside an immersive brand showcase that reflected AIMS’ premium positioning and global ambitions.

A key highlight of the event was a corporate presentation tracing the growth of AIMS since its establishment in 2015, including landmark partnerships with Borussia Dortmund in 2022, the ASEAN Football Federation in 2023, Tottenham Hotspur in 2024, and Lamborghini in 2026.

“This is not merely an office opening — it is a declaration of our long-term commitment to Indonesia and to every trader who has placed their trust in us,” said Mr. Windy Alexandra, CEO of AIMS Indonesia. “Fund safety remains at the core of everything we do. Receiving our BAPPEBTI licence validates our approach and affirms that AIMS Indonesia is here to serve the market with integrity, transparency, and the highest standards of compliance.”

With a population exceeding 270 million, growing digital adoption, and rising interest in financial markets, Indonesia represents one of the region’s most important growth opportunities for AIMS.

The launch of AIMS Indonesia marks the beginning of a significant new chapter for the Group. Backed by a strong local leadership team, BAPPEBTI regulatory approval, and the global AIMS ecosystem, AIMS Indonesia is positioned to become a leading force in one of Southeast Asia’s most dynamic financial markets.

Windy Alexandra, CEO of AIMS Indonesia and his team

About AIMS

AIMS is a brand with an 11-year industry heritage and a trusted financial broker for institutional and individual traders worldwide. With a global presence spanning more than 21 countries and regions, the is renowned for its high-performance trading platforms, highly competitive spreads, and client-centric service philosophy, continuously driving development and innovation in the global trading industry.

Press Inquiries

Benson Low
media [at] aimsfx.com
https://aimsfx.com/

Allschwil, Switzerland, May 28, 2026

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD 13.3 million to Basilea to continue the development of Basilea’s novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis.

David Veitch, Chief Executive Officer of Basilea, said: “Basilea is proud to be developing ceftibuten-ledaborbactam in partnership with BARDA. This funding helps us to further advance this novel antibiotic, including the preparation of the clinical phase 3 program. By advancing this promising candidate, we are potentially addressing the critical unmet need for the oral treatment of cUTIs caused by multidrug-resistant Gram-negative bacteria.”

After the current tranche of USD 13.3 million, a total of USD 25 million have been committed by BARDA. The contract^[1] could provide up to USD 133 million of additional non-dilutive funding.

About beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations

Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections caused by multidrug-resistant bacterial pathogens.

About ceftibuten-ledaborbactam etzadroxil

Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales.^[2] Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use.

About complicated urinary tract infections (cUTI)

Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options.^[3] Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48).

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

This ad hoc announcement can be downloaded from www.basilea.com.

References

1. This project has been funded in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50123C00050.
2. J. A. Karlowsky, M. G. Wise, M. A. Hackel et al. Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection. Antimicrobial Agents and Chemotherapy 2022, Nov 15;66(11):e0093422
3. T. P. Lodise, T. Chopra, B. H. Nathanson et al. Epidemiology of Complicated Urinary Tract Infections due to Enterobacterales Among Adult Patients Presenting in Emergency Departments Across the United States. Open Forum Infectious Diseases 2022, Jun 24;9(7):ofac315.

Attachment

• Ad hoc release

With immediate effect, the Board has appointed Debrako BV, permanently represented by Mr. Koen De Brabander, as ad interim presiding member of the Management Committee. In this capacity, Koen De Brabander will lead the management team and serve as the Board’s primary interlocutor on matters of day-to-day management. The management team will ensure full continuity of operations and execution against the company’s strategic priorities.

Peter Mulroy, Chairman of the Board of Directors, commented: “On behalf of the entire Board, I want to thank Nicolas warmly for what he built at Banqup. He came in at a critical moment and drove a genuine transformation, delivering on the Belgian e-invoicing rollout and helping position us ahead of one of the most significant regulatory opportunities in our market. We wish him well. I have full confidence in Koen and the management team to carry that work forward with the focus and momentum our shareholders expect.”

Financial Calendar:
25 August 2026: Publication of the H1 2026 results (webcast)
13 November 2026: Publication of the Q3 2026 Business Update

Contact
Vincent Nagels
Investor Relations
Banqup Group
Investor.relations@banqup.com

About Banqup Group

Banqup Group delivers integrated cloud-based SaaS solutions to streamline business transactions across the
entire lifecycle, from e-invoicing and e-payments to tax reporting. Banqup, our solution for businesses, unifies
purchase-to-pay, order-to-cash, e-invoicing compliance, and e-payments into one secure platform, removing the
complexity of juggling disconnected tools. eFaktura World, our solution for governments, is a comprehensive
digital platform designed for tax administrations to implement e-invoicing and streamline both B2G and B2B tax
reporting flows. To learn more about Banqup Group and our solutions, please visit our website: Banqup Group

Cautionary note regarding forward-looking statements: The statements contained herein may include prospects, statements of future expectations, opinions, and other forward-looking statements in relation to the expected future performance of Banqup Group and the markets in which it is active. Such forward-looking statements are based on management’s current views and assumptions regarding future events. By nature, they involve known and unknown risks, uncertainties, and other factors that appear justified at the time at which they are made but may not turn out to be accurate. Actual results, performance or events may, therefore, differ materially from those expressed or implied in such forward-looking statements. Except as required by applicable law, Banqup Group does not undertake any obligation to update, clarify or correct any forward-looking statements contained in this press release in light of new information, future events or otherwise and disclaims any liability in respect hereto. The reader is cautioned not to place undue reliance on forward-looking statements.

Attachment

• 26-05-28 Banqup Press release